GNOG vs. BTEK ETF Comparison

Comparison of Global X Genomics & Biotechnology UCITS ETF USD Acc GBP (GNOG) to iShares Nasdaq US Biotech ETF USD Acc (BTEK)

GNOG

Global X Genomics & Biotechnology UCITS ETF USD Acc GBP

GNOG Description

NA

Grade (RS Rating)

Last Trade

£5.64

Average Daily Volume

2,952

Number of Holdings ^*

8

* may have additional holdings in another (foreign) market

BTEK

iShares Nasdaq US Biotech ETF USD Acc

BTEK Description

The Fund seeks to track the performance of the NASDAQ Biotechnology Index (Net Total Return) .

Grade (RS Rating)

Last Trade

£4.85

Average Daily Volume

20,457

Number of Holdings ^*

13

* may have additional holdings in another (foreign) market

Performance

Period	GNOG	BTEK
30 Days	-12.24%	-5.04%
60 Days	-18.80%	-6.45%
90 Days	-7.55%	-3.79%
12 Months	-18.01%	1.14%

6 Overlapping Holdings

	Symbol	Grade	Weight in GNOG	Weight in BTEK	Overlap
	0A3M	F	3.38%	0.95%	0.95%
	0A45	B	5.13%	4.36%	4.36%
	0HI3	F	3.38%	0.31%	0.31%
	0J8Z	F	3.93%	2.1%	2.1%
	0L35	B	4.41%	1.22%	1.22%
	0QZU	D	2.0%	8.26%	2.0%

GNOG Overweight 2 Positions Relative to BTEK

	Symbol	Grade	Weight
	0HAV	D	4.9%
	0RLT	A	4.02%

GNOG Underweight 7 Positions Relative to BTEK

	Symbol	Grade	Weight
	0R1B	D	-3.18%
	0O59	B	-1.43%
	0JAV	B	-0.41%
	0JDK	D	-0.36%
	0RDV	F	-0.08%
	0A3S	C	-0.06%
	0HFR	F	-0.03%

GNOG: Top Represented Industries & Keywords

Industries:

Keywords: Biotechnology Cancer Genomics Genotyping Infectious Diseases Orphan Drugs Rare Diseases Agilent Technologies Analytical Chemistry Asset Management Astrazeneca Biopharmaceutical Cancer Immunotherapy Chemical Pathology Chemistry Chromatography Dna Sequencing Duchenne Muscular Dystrophy Gene Expression Gene Therapy

BTEK: Top Represented Industries & Keywords

Industries:

Keywords: Biotechnology Cancer Alzheimer's Disease Biopharmaceutical Cancer Immunotherapy Infectious Diseases Influenza Malaria Medical Specialties Melanoma Metastatic Non Small Cell Lung Cancer Multiple Sclerosis Organ Systems Orphan Drugs Pancreatic Cancer Rare Diseases Vaccine Alzheimer's Diseases Astrazeneca Clinical Research